Article info
PDFOriginal research
Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients
- Correspondence to Dr Rubén Iglesias Gómez, Pharmacy, Hospital Universitari i Politècnic La Fe, Valencia, Spain; iglesis_rub{at}gva.es
Citation
Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients
Publication history
- Received February 19, 2021
- Accepted July 5, 2021
- First published July 28, 2021.
Online issue publication
March 07, 2022
Article Versions
- Previous version (7 March 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage